nodes	percent_of_prediction	percent_of_DWPC	metapath
Paroxetine—CYP2B6—Raloxifene—osteoporosis	0.0637	0.12	CbGbCtD
Paroxetine—CYP2B6—Ethinyl Estradiol—osteoporosis	0.0615	0.115	CbGbCtD
Paroxetine—CYP2C9—Estropipate—osteoporosis	0.0504	0.0947	CbGbCtD
Paroxetine—CYP2B6—Cholecalciferol—osteoporosis	0.0491	0.0923	CbGbCtD
Paroxetine—CYP2C8—Raloxifene—osteoporosis	0.0482	0.0906	CbGbCtD
Paroxetine—CYP2C8—Ethinyl Estradiol—osteoporosis	0.0466	0.0875	CbGbCtD
Paroxetine—CYP2C8—Cholecalciferol—osteoporosis	0.0372	0.0699	CbGbCtD
Paroxetine—ABCB1—Ethinyl Estradiol—osteoporosis	0.0315	0.0592	CbGbCtD
Paroxetine—CYP2C8—Estradiol—osteoporosis	0.03	0.0564	CbGbCtD
Paroxetine—CYP2C9—Cholecalciferol—osteoporosis	0.026	0.0488	CbGbCtD
Paroxetine—CYP2D6—Cholecalciferol—osteoporosis	0.0237	0.0446	CbGbCtD
Paroxetine—ABCB1—Conjugated Estrogens—osteoporosis	0.0231	0.0435	CbGbCtD
Paroxetine—CYP2C9—Estradiol—osteoporosis	0.0209	0.0393	CbGbCtD
Paroxetine—ABCB1—Estradiol—osteoporosis	0.0203	0.0382	CbGbCtD
Paroxetine—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000113	0.000282	CcSEcCtD
Paroxetine—Fatigue—Ethinyl Estradiol—osteoporosis	0.000113	0.000282	CcSEcCtD
Paroxetine—Pruritus—Alendronate—osteoporosis	0.000112	0.000281	CcSEcCtD
Paroxetine—Dyspepsia—Risedronate—osteoporosis	0.000112	0.00028	CcSEcCtD
Paroxetine—Eye disorder—Estradiol—osteoporosis	0.000112	0.00028	CcSEcCtD
Paroxetine—Tinnitus—Estradiol—osteoporosis	0.000112	0.00028	CcSEcCtD
Paroxetine—Constipation—Ethinyl Estradiol—osteoporosis	0.000112	0.000279	CcSEcCtD
Paroxetine—Confusional state—Zoledronate—osteoporosis	0.000112	0.000279	CcSEcCtD
Paroxetine—Hypersensitivity—Calcitriol—osteoporosis	0.000112	0.000279	CcSEcCtD
Paroxetine—Cardiac disorder—Estradiol—osteoporosis	0.000111	0.000278	CcSEcCtD
Paroxetine—Flushing—Estradiol—osteoporosis	0.000111	0.000278	CcSEcCtD
Paroxetine—Arthralgia—Conjugated Estrogens—osteoporosis	0.000111	0.000278	CcSEcCtD
Paroxetine—Chest pain—Conjugated Estrogens—osteoporosis	0.000111	0.000278	CcSEcCtD
Paroxetine—Myalgia—Conjugated Estrogens—osteoporosis	0.000111	0.000278	CcSEcCtD
Paroxetine—Asthenia—Ibandronate—osteoporosis	0.000111	0.000277	CcSEcCtD
Paroxetine—Anxiety—Conjugated Estrogens—osteoporosis	0.000111	0.000277	CcSEcCtD
Paroxetine—Nausea—Etidronic acid—osteoporosis	0.000111	0.000277	CcSEcCtD
Paroxetine—Anaphylactic shock—Zoledronate—osteoporosis	0.000111	0.000277	CcSEcCtD
Paroxetine—Oedema—Zoledronate—osteoporosis	0.000111	0.000277	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.00011	0.000276	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.00011	0.000276	CcSEcCtD
Paroxetine—Diarrhoea—Estropipate—osteoporosis	0.00011	0.000276	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Risedronate—osteoporosis	0.00011	0.000275	CcSEcCtD
Paroxetine—Infection—Zoledronate—osteoporosis	0.00011	0.000275	CcSEcCtD
Paroxetine—Fatigue—Risedronate—osteoporosis	0.00011	0.000275	CcSEcCtD
Paroxetine—Insomnia—Pamidronate—osteoporosis	0.00011	0.000274	CcSEcCtD
Paroxetine—Pruritus—Ibandronate—osteoporosis	0.000109	0.000274	CcSEcCtD
Paroxetine—Constipation—Risedronate—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Pain—Risedronate—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Angiopathy—Estradiol—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Shock—Zoledronate—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Paraesthesia—Pamidronate—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Diarrhoea—Alendronate—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Asthenia—Calcitriol—osteoporosis	0.000109	0.000272	CcSEcCtD
Paroxetine—Nervous system disorder—Zoledronate—osteoporosis	0.000109	0.000271	CcSEcCtD
Paroxetine—Immune system disorder—Estradiol—osteoporosis	0.000109	0.000271	CcSEcCtD
Paroxetine—Thrombocytopenia—Zoledronate—osteoporosis	0.000108	0.000271	CcSEcCtD
Paroxetine—Mediastinal disorder—Estradiol—osteoporosis	0.000108	0.00027	CcSEcCtD
Paroxetine—Dyspnoea—Pamidronate—osteoporosis	0.000108	0.00027	CcSEcCtD
Paroxetine—Tachycardia—Zoledronate—osteoporosis	0.000108	0.00027	CcSEcCtD
Paroxetine—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000108	0.000269	CcSEcCtD
Paroxetine—Chills—Estradiol—osteoporosis	0.000108	0.000269	CcSEcCtD
Paroxetine—Somnolence—Pamidronate—osteoporosis	0.000108	0.000269	CcSEcCtD
Paroxetine—Skin disorder—Zoledronate—osteoporosis	0.000108	0.000269	CcSEcCtD
Paroxetine—Pruritus—Calcitriol—osteoporosis	0.000107	0.000268	CcSEcCtD
Paroxetine—Hyperhidrosis—Zoledronate—osteoporosis	0.000107	0.000267	CcSEcCtD
Paroxetine—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000107	0.000267	CcSEcCtD
Paroxetine—Diarrhoea—Raloxifene—osteoporosis	0.000107	0.000267	CcSEcCtD
Paroxetine—Dyspepsia—Pamidronate—osteoporosis	0.000107	0.000267	CcSEcCtD
Paroxetine—Dizziness—Estropipate—osteoporosis	0.000107	0.000267	CcSEcCtD
Paroxetine—Anaphylactic shock—Conjugated Estrogens—osteoporosis	0.000107	0.000266	CcSEcCtD
Paroxetine—Oedema—Conjugated Estrogens—osteoporosis	0.000107	0.000266	CcSEcCtD
Paroxetine—Alopecia—Estradiol—osteoporosis	0.000106	0.000265	CcSEcCtD
Paroxetine—Infection—Conjugated Estrogens—osteoporosis	0.000106	0.000265	CcSEcCtD
Paroxetine—Diarrhoea—Ibandronate—osteoporosis	0.000106	0.000265	CcSEcCtD
Paroxetine—Decreased appetite—Pamidronate—osteoporosis	0.000105	0.000263	CcSEcCtD
Paroxetine—Mental disorder—Estradiol—osteoporosis	0.000105	0.000263	CcSEcCtD
Paroxetine—Dizziness—Alendronate—osteoporosis	0.000105	0.000263	CcSEcCtD
Paroxetine—Shock—Conjugated Estrogens—osteoporosis	0.000105	0.000262	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000105	0.000261	CcSEcCtD
Paroxetine—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000105	0.000261	CcSEcCtD
Paroxetine—Malnutrition—Estradiol—osteoporosis	0.000105	0.000261	CcSEcCtD
Paroxetine—Erythema—Estradiol—osteoporosis	0.000105	0.000261	CcSEcCtD
Paroxetine—Fatigue—Pamidronate—osteoporosis	0.000105	0.000261	CcSEcCtD
Paroxetine—Gastrointestinal pain—Risedronate—osteoporosis	0.000104	0.000261	CcSEcCtD
Paroxetine—Tachycardia—Conjugated Estrogens—osteoporosis	0.000104	0.00026	CcSEcCtD
Paroxetine—Urticaria—Ethinyl Estradiol—osteoporosis	0.000104	0.00026	CcSEcCtD
Paroxetine—Pain—Pamidronate—osteoporosis	0.000104	0.000259	CcSEcCtD
Paroxetine—Constipation—Pamidronate—osteoporosis	0.000104	0.000259	CcSEcCtD
Paroxetine—Diarrhoea—Calcitriol—osteoporosis	0.000104	0.000259	CcSEcCtD
Paroxetine—Skin disorder—Conjugated Estrogens—osteoporosis	0.000104	0.000259	CcSEcCtD
Paroxetine—Hypotension—Zoledronate—osteoporosis	0.000103	0.000258	CcSEcCtD
Paroxetine—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000103	0.000258	CcSEcCtD
Paroxetine—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000103	0.000258	CcSEcCtD
Paroxetine—Dizziness—Raloxifene—osteoporosis	0.000103	0.000258	CcSEcCtD
Paroxetine—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000103	0.000258	CcSEcCtD
Paroxetine—Flatulence—Estradiol—osteoporosis	0.000103	0.000257	CcSEcCtD
Paroxetine—Tension—Estradiol—osteoporosis	0.000103	0.000256	CcSEcCtD
Paroxetine—Vomiting—Estropipate—osteoporosis	0.000103	0.000256	CcSEcCtD
Paroxetine—Dysgeusia—Estradiol—osteoporosis	0.000102	0.000256	CcSEcCtD
Paroxetine—Dizziness—Ibandronate—osteoporosis	0.000102	0.000256	CcSEcCtD
Paroxetine—Rash—Estropipate—osteoporosis	0.000102	0.000254	CcSEcCtD
Paroxetine—Dermatitis—Estropipate—osteoporosis	0.000102	0.000254	CcSEcCtD
Paroxetine—Nervousness—Estradiol—osteoporosis	0.000102	0.000254	CcSEcCtD
Paroxetine—Urticaria—Risedronate—osteoporosis	0.000101	0.000253	CcSEcCtD
Paroxetine—Back pain—Estradiol—osteoporosis	0.000101	0.000253	CcSEcCtD
Paroxetine—Headache—Estropipate—osteoporosis	0.000101	0.000253	CcSEcCtD
Paroxetine—Vomiting—Alendronate—osteoporosis	0.000101	0.000252	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000101	0.000252	CcSEcCtD
Paroxetine—Abdominal pain—Risedronate—osteoporosis	0.000101	0.000252	CcSEcCtD
Paroxetine—Body temperature increased—Risedronate—osteoporosis	0.000101	0.000252	CcSEcCtD
Paroxetine—Muscle spasms—Estradiol—osteoporosis	0.000101	0.000251	CcSEcCtD
Paroxetine—Rash—Alendronate—osteoporosis	0.0001	0.00025	CcSEcCtD
Paroxetine—Insomnia—Zoledronate—osteoporosis	0.0001	0.00025	CcSEcCtD
Paroxetine—Dermatitis—Alendronate—osteoporosis	0.0001	0.00025	CcSEcCtD
Paroxetine—Feeling abnormal—Pamidronate—osteoporosis	9.99e-05	0.00025	CcSEcCtD
Paroxetine—Hypotension—Conjugated Estrogens—osteoporosis	9.97e-05	0.000249	CcSEcCtD
Paroxetine—Headache—Alendronate—osteoporosis	9.96e-05	0.000249	CcSEcCtD
Paroxetine—Paraesthesia—Zoledronate—osteoporosis	9.95e-05	0.000248	CcSEcCtD
Paroxetine—Vomiting—Raloxifene—osteoporosis	9.94e-05	0.000248	CcSEcCtD
Paroxetine—Gastrointestinal pain—Pamidronate—osteoporosis	9.91e-05	0.000248	CcSEcCtD
Paroxetine—Dyspnoea—Zoledronate—osteoporosis	9.87e-05	0.000247	CcSEcCtD
Paroxetine—Rash—Raloxifene—osteoporosis	9.86e-05	0.000246	CcSEcCtD
Paroxetine—Dermatitis—Raloxifene—osteoporosis	9.85e-05	0.000246	CcSEcCtD
Paroxetine—Somnolence—Zoledronate—osteoporosis	9.85e-05	0.000246	CcSEcCtD
Paroxetine—Vomiting—Ibandronate—osteoporosis	9.84e-05	0.000246	CcSEcCtD
Paroxetine—Tremor—Estradiol—osteoporosis	9.8e-05	0.000245	CcSEcCtD
Paroxetine—Headache—Raloxifene—osteoporosis	9.79e-05	0.000245	CcSEcCtD
Paroxetine—Rash—Ibandronate—osteoporosis	9.76e-05	0.000244	CcSEcCtD
Paroxetine—Dermatitis—Ibandronate—osteoporosis	9.75e-05	0.000244	CcSEcCtD
Paroxetine—Dyspepsia—Zoledronate—osteoporosis	9.75e-05	0.000244	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	9.72e-05	0.000243	CcSEcCtD
Paroxetine—Ill-defined disorder—Estradiol—osteoporosis	9.7e-05	0.000242	CcSEcCtD
Paroxetine—Headache—Ibandronate—osteoporosis	9.7e-05	0.000242	CcSEcCtD
Paroxetine—Insomnia—Conjugated Estrogens—osteoporosis	9.65e-05	0.000241	CcSEcCtD
Paroxetine—Hypersensitivity—Ethinyl Estradiol—osteoporosis	9.64e-05	0.000241	CcSEcCtD
Paroxetine—Vomiting—Calcitriol—osteoporosis	9.63e-05	0.000241	CcSEcCtD
Paroxetine—Decreased appetite—Zoledronate—osteoporosis	9.63e-05	0.00024	CcSEcCtD
Paroxetine—Agitation—Estradiol—osteoporosis	9.61e-05	0.00024	CcSEcCtD
Paroxetine—Nausea—Estropipate—osteoporosis	9.59e-05	0.000239	CcSEcCtD
Paroxetine—Abdominal pain—Pamidronate—osteoporosis	9.59e-05	0.000239	CcSEcCtD
Paroxetine—Body temperature increased—Pamidronate—osteoporosis	9.59e-05	0.000239	CcSEcCtD
Paroxetine—Paraesthesia—Conjugated Estrogens—osteoporosis	9.58e-05	0.000239	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Zoledronate—osteoporosis	9.56e-05	0.000239	CcSEcCtD
Paroxetine—Angioedema—Estradiol—osteoporosis	9.56e-05	0.000239	CcSEcCtD
Paroxetine—Rash—Calcitriol—osteoporosis	9.55e-05	0.000239	CcSEcCtD
Paroxetine—Fatigue—Zoledronate—osteoporosis	9.55e-05	0.000239	CcSEcCtD
Paroxetine—Dermatitis—Calcitriol—osteoporosis	9.54e-05	0.000238	CcSEcCtD
Paroxetine—Dyspnoea—Conjugated Estrogens—osteoporosis	9.51e-05	0.000237	CcSEcCtD
Paroxetine—Headache—Calcitriol—osteoporosis	9.49e-05	0.000237	CcSEcCtD
Paroxetine—Somnolence—Conjugated Estrogens—osteoporosis	9.48e-05	0.000237	CcSEcCtD
Paroxetine—Pain—Zoledronate—osteoporosis	9.47e-05	0.000237	CcSEcCtD
Paroxetine—Constipation—Zoledronate—osteoporosis	9.47e-05	0.000237	CcSEcCtD
Paroxetine—Nausea—Alendronate—osteoporosis	9.44e-05	0.000236	CcSEcCtD
Paroxetine—Malaise—Estradiol—osteoporosis	9.43e-05	0.000236	CcSEcCtD
Paroxetine—Hypersensitivity—Risedronate—osteoporosis	9.4e-05	0.000235	CcSEcCtD
Paroxetine—Vertigo—Estradiol—osteoporosis	9.4e-05	0.000235	CcSEcCtD
Paroxetine—Dyspepsia—Conjugated Estrogens—osteoporosis	9.39e-05	0.000234	CcSEcCtD
Paroxetine—Asthenia—Ethinyl Estradiol—osteoporosis	9.39e-05	0.000234	CcSEcCtD
Paroxetine—Syncope—Estradiol—osteoporosis	9.38e-05	0.000234	CcSEcCtD
Paroxetine—Nausea—Raloxifene—osteoporosis	9.29e-05	0.000232	CcSEcCtD
Paroxetine—Decreased appetite—Conjugated Estrogens—osteoporosis	9.27e-05	0.000232	CcSEcCtD
Paroxetine—Pruritus—Ethinyl Estradiol—osteoporosis	9.26e-05	0.000231	CcSEcCtD
Paroxetine—Palpitations—Estradiol—osteoporosis	9.24e-05	0.000231	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	9.21e-05	0.00023	CcSEcCtD
Paroxetine—Fatigue—Conjugated Estrogens—osteoporosis	9.19e-05	0.00023	CcSEcCtD
Paroxetine—Nausea—Ibandronate—osteoporosis	9.19e-05	0.00023	CcSEcCtD
Paroxetine—Loss of consciousness—Estradiol—osteoporosis	9.19e-05	0.00023	CcSEcCtD
Paroxetine—Asthenia—Risedronate—osteoporosis	9.15e-05	0.000229	CcSEcCtD
Paroxetine—Feeling abnormal—Zoledronate—osteoporosis	9.13e-05	0.000228	CcSEcCtD
Paroxetine—Cough—Estradiol—osteoporosis	9.13e-05	0.000228	CcSEcCtD
Paroxetine—Pain—Conjugated Estrogens—osteoporosis	9.12e-05	0.000228	CcSEcCtD
Paroxetine—Constipation—Conjugated Estrogens—osteoporosis	9.12e-05	0.000228	CcSEcCtD
Paroxetine—Gastrointestinal pain—Zoledronate—osteoporosis	9.06e-05	0.000226	CcSEcCtD
Paroxetine—Hypertension—Estradiol—osteoporosis	9.03e-05	0.000226	CcSEcCtD
Paroxetine—Pruritus—Risedronate—osteoporosis	9.02e-05	0.000225	CcSEcCtD
Paroxetine—Nausea—Calcitriol—osteoporosis	9e-05	0.000225	CcSEcCtD
Paroxetine—Diarrhoea—Ethinyl Estradiol—osteoporosis	8.95e-05	0.000224	CcSEcCtD
Paroxetine—Hypersensitivity—Pamidronate—osteoporosis	8.93e-05	0.000223	CcSEcCtD
Paroxetine—Arthralgia—Estradiol—osteoporosis	8.9e-05	0.000222	CcSEcCtD
Paroxetine—Chest pain—Estradiol—osteoporosis	8.9e-05	0.000222	CcSEcCtD
Paroxetine—Myalgia—Estradiol—osteoporosis	8.9e-05	0.000222	CcSEcCtD
Paroxetine—Anxiety—Estradiol—osteoporosis	8.87e-05	0.000222	CcSEcCtD
Paroxetine—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	8.84e-05	0.000221	CcSEcCtD
Paroxetine—Urticaria—Zoledronate—osteoporosis	8.8e-05	0.00022	CcSEcCtD
Paroxetine—Discomfort—Estradiol—osteoporosis	8.8e-05	0.00022	CcSEcCtD
Paroxetine—Body temperature increased—Zoledronate—osteoporosis	8.76e-05	0.000219	CcSEcCtD
Paroxetine—Abdominal pain—Zoledronate—osteoporosis	8.76e-05	0.000219	CcSEcCtD
Paroxetine—Diarrhoea—Risedronate—osteoporosis	8.73e-05	0.000218	CcSEcCtD
Paroxetine—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	8.72e-05	0.000218	CcSEcCtD
Paroxetine—Dry mouth—Estradiol—osteoporosis	8.71e-05	0.000217	CcSEcCtD
Paroxetine—Asthenia—Pamidronate—osteoporosis	8.7e-05	0.000217	CcSEcCtD
Paroxetine—Dizziness—Ethinyl Estradiol—osteoporosis	8.65e-05	0.000216	CcSEcCtD
Paroxetine—Confusional state—Estradiol—osteoporosis	8.61e-05	0.000215	CcSEcCtD
Paroxetine—Pruritus—Pamidronate—osteoporosis	8.58e-05	0.000214	CcSEcCtD
Paroxetine—Oedema—Estradiol—osteoporosis	8.54e-05	0.000213	CcSEcCtD
Paroxetine—Anaphylactic shock—Estradiol—osteoporosis	8.54e-05	0.000213	CcSEcCtD
Paroxetine—Infection—Estradiol—osteoporosis	8.48e-05	0.000212	CcSEcCtD
Paroxetine—Urticaria—Conjugated Estrogens—osteoporosis	8.47e-05	0.000212	CcSEcCtD
Paroxetine—Dizziness—Risedronate—osteoporosis	8.43e-05	0.000211	CcSEcCtD
Paroxetine—Body temperature increased—Conjugated Estrogens—osteoporosis	8.43e-05	0.000211	CcSEcCtD
Paroxetine—Abdominal pain—Conjugated Estrogens—osteoporosis	8.43e-05	0.000211	CcSEcCtD
Paroxetine—Shock—Estradiol—osteoporosis	8.4e-05	0.00021	CcSEcCtD
Paroxetine—Nervous system disorder—Estradiol—osteoporosis	8.37e-05	0.000209	CcSEcCtD
Paroxetine—Tachycardia—Estradiol—osteoporosis	8.33e-05	0.000208	CcSEcCtD
Paroxetine—Vomiting—Ethinyl Estradiol—osteoporosis	8.32e-05	0.000208	CcSEcCtD
Paroxetine—Diarrhoea—Pamidronate—osteoporosis	8.3e-05	0.000207	CcSEcCtD
Paroxetine—Skin disorder—Estradiol—osteoporosis	8.29e-05	0.000207	CcSEcCtD
Paroxetine—Hyperhidrosis—Estradiol—osteoporosis	8.25e-05	0.000206	CcSEcCtD
Paroxetine—Rash—Ethinyl Estradiol—osteoporosis	8.25e-05	0.000206	CcSEcCtD
Paroxetine—Dermatitis—Ethinyl Estradiol—osteoporosis	8.24e-05	0.000206	CcSEcCtD
Paroxetine—Headache—Ethinyl Estradiol—osteoporosis	8.2e-05	0.000205	CcSEcCtD
Paroxetine—Hypersensitivity—Zoledronate—osteoporosis	8.16e-05	0.000204	CcSEcCtD
Paroxetine—Vomiting—Risedronate—osteoporosis	8.11e-05	0.000203	CcSEcCtD
Paroxetine—Rash—Risedronate—osteoporosis	8.04e-05	0.000201	CcSEcCtD
Paroxetine—Dermatitis—Risedronate—osteoporosis	8.03e-05	0.000201	CcSEcCtD
Paroxetine—Dizziness—Pamidronate—osteoporosis	8.02e-05	0.0002	CcSEcCtD
Paroxetine—Headache—Risedronate—osteoporosis	7.99e-05	0.0002	CcSEcCtD
Paroxetine—Asthenia—Zoledronate—osteoporosis	7.95e-05	0.000198	CcSEcCtD
Paroxetine—Hypersensitivity—Conjugated Estrogens—osteoporosis	7.86e-05	0.000196	CcSEcCtD
Paroxetine—Pruritus—Zoledronate—osteoporosis	7.84e-05	0.000196	CcSEcCtD
Paroxetine—Musculoskeletal discomfort—Estradiol—osteoporosis	7.78e-05	0.000194	CcSEcCtD
Paroxetine—Nausea—Ethinyl Estradiol—osteoporosis	7.77e-05	0.000194	CcSEcCtD
Paroxetine—Insomnia—Estradiol—osteoporosis	7.72e-05	0.000193	CcSEcCtD
Paroxetine—Vomiting—Pamidronate—osteoporosis	7.71e-05	0.000193	CcSEcCtD
Paroxetine—Paraesthesia—Estradiol—osteoporosis	7.66e-05	0.000191	CcSEcCtD
Paroxetine—Asthenia—Conjugated Estrogens—osteoporosis	7.65e-05	0.000191	CcSEcCtD
Paroxetine—Rash—Pamidronate—osteoporosis	7.65e-05	0.000191	CcSEcCtD
Paroxetine—Dermatitis—Pamidronate—osteoporosis	7.64e-05	0.000191	CcSEcCtD
Paroxetine—Dyspnoea—Estradiol—osteoporosis	7.61e-05	0.00019	CcSEcCtD
Paroxetine—Headache—Pamidronate—osteoporosis	7.6e-05	0.00019	CcSEcCtD
Paroxetine—Somnolence—Estradiol—osteoporosis	7.59e-05	0.00019	CcSEcCtD
Paroxetine—Diarrhoea—Zoledronate—osteoporosis	7.58e-05	0.000189	CcSEcCtD
Paroxetine—Nausea—Risedronate—osteoporosis	7.58e-05	0.000189	CcSEcCtD
Paroxetine—Pruritus—Conjugated Estrogens—osteoporosis	7.55e-05	0.000188	CcSEcCtD
Paroxetine—Dyspepsia—Estradiol—osteoporosis	7.51e-05	0.000188	CcSEcCtD
Paroxetine—Decreased appetite—Estradiol—osteoporosis	7.42e-05	0.000185	CcSEcCtD
Paroxetine—Gastrointestinal disorder—Estradiol—osteoporosis	7.37e-05	0.000184	CcSEcCtD
Paroxetine—Fatigue—Estradiol—osteoporosis	7.36e-05	0.000184	CcSEcCtD
Paroxetine—Dizziness—Zoledronate—osteoporosis	7.32e-05	0.000183	CcSEcCtD
Paroxetine—Constipation—Estradiol—osteoporosis	7.3e-05	0.000182	CcSEcCtD
Paroxetine—Pain—Estradiol—osteoporosis	7.3e-05	0.000182	CcSEcCtD
Paroxetine—Diarrhoea—Conjugated Estrogens—osteoporosis	7.3e-05	0.000182	CcSEcCtD
Paroxetine—Nausea—Pamidronate—osteoporosis	7.2e-05	0.00018	CcSEcCtD
Paroxetine—Dizziness—Conjugated Estrogens—osteoporosis	7.05e-05	0.000176	CcSEcCtD
Paroxetine—Vomiting—Zoledronate—osteoporosis	7.04e-05	0.000176	CcSEcCtD
Paroxetine—Feeling abnormal—Estradiol—osteoporosis	7.03e-05	0.000176	CcSEcCtD
Paroxetine—Rash—Zoledronate—osteoporosis	6.98e-05	0.000174	CcSEcCtD
Paroxetine—Gastrointestinal pain—Estradiol—osteoporosis	6.98e-05	0.000174	CcSEcCtD
Paroxetine—Dermatitis—Zoledronate—osteoporosis	6.98e-05	0.000174	CcSEcCtD
Paroxetine—Headache—Zoledronate—osteoporosis	6.94e-05	0.000173	CcSEcCtD
Paroxetine—Vomiting—Conjugated Estrogens—osteoporosis	6.78e-05	0.000169	CcSEcCtD
Paroxetine—Urticaria—Estradiol—osteoporosis	6.78e-05	0.000169	CcSEcCtD
Paroxetine—Abdominal pain—Estradiol—osteoporosis	6.75e-05	0.000169	CcSEcCtD
Paroxetine—Body temperature increased—Estradiol—osteoporosis	6.75e-05	0.000169	CcSEcCtD
Paroxetine—Rash—Conjugated Estrogens—osteoporosis	6.72e-05	0.000168	CcSEcCtD
Paroxetine—Dermatitis—Conjugated Estrogens—osteoporosis	6.72e-05	0.000168	CcSEcCtD
Paroxetine—Headache—Conjugated Estrogens—osteoporosis	6.68e-05	0.000167	CcSEcCtD
Paroxetine—Nausea—Zoledronate—osteoporosis	6.58e-05	0.000164	CcSEcCtD
Paroxetine—Nausea—Conjugated Estrogens—osteoporosis	6.33e-05	0.000158	CcSEcCtD
Paroxetine—Hypersensitivity—Estradiol—osteoporosis	6.29e-05	0.000157	CcSEcCtD
Paroxetine—Asthenia—Estradiol—osteoporosis	6.12e-05	0.000153	CcSEcCtD
Paroxetine—Pruritus—Estradiol—osteoporosis	6.04e-05	0.000151	CcSEcCtD
Paroxetine—Diarrhoea—Estradiol—osteoporosis	5.84e-05	0.000146	CcSEcCtD
Paroxetine—Dizziness—Estradiol—osteoporosis	5.64e-05	0.000141	CcSEcCtD
Paroxetine—Vomiting—Estradiol—osteoporosis	5.43e-05	0.000136	CcSEcCtD
Paroxetine—Rash—Estradiol—osteoporosis	5.38e-05	0.000134	CcSEcCtD
Paroxetine—Dermatitis—Estradiol—osteoporosis	5.38e-05	0.000134	CcSEcCtD
Paroxetine—Headache—Estradiol—osteoporosis	5.35e-05	0.000134	CcSEcCtD
Paroxetine—Nausea—Estradiol—osteoporosis	5.07e-05	0.000127	CcSEcCtD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.29e-05	0.00034	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—RAP1A—osteoporosis	2.29e-05	0.00034	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.29e-05	0.00034	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTH—osteoporosis	2.28e-05	0.000339	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTH—osteoporosis	2.27e-05	0.000337	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTH—osteoporosis	2.26e-05	0.000336	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—RAP1A—osteoporosis	2.24e-05	0.000333	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTH—osteoporosis	2.24e-05	0.000333	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—RAP1A—osteoporosis	2.23e-05	0.000331	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—KL—osteoporosis	2.23e-05	0.000331	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CNR2—osteoporosis	2.23e-05	0.00033	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—RAP1A—osteoporosis	2.22e-05	0.00033	CbGpPWpGaD
Paroxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.22e-05	0.000329	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CNR2—osteoporosis	2.21e-05	0.000328	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—IDH2—osteoporosis	2.21e-05	0.000328	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—ADCY5—osteoporosis	2.21e-05	0.000328	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CNR2—osteoporosis	2.21e-05	0.000327	CbGpPWpGaD
Paroxetine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.2e-05	0.000327	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—RAP1A—osteoporosis	2.2e-05	0.000327	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—ADCY5—osteoporosis	2.2e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—osteoporosis	2.2e-05	0.000326	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—ADCY5—osteoporosis	2.19e-05	0.000325	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—NFATC1—osteoporosis	2.19e-05	0.000325	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CNR2—osteoporosis	2.18e-05	0.000324	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—NFATC1—osteoporosis	2.18e-05	0.000323	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—POMC—osteoporosis	2.18e-05	0.000323	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—DKK1—osteoporosis	2.17e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—NFATC1—osteoporosis	2.17e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—ADCY5—osteoporosis	2.17e-05	0.000322	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—DKK1—osteoporosis	2.16e-05	0.000321	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—TPI1—osteoporosis	2.16e-05	0.00032	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—DKK1—osteoporosis	2.15e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ENO1—osteoporosis	2.15e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—NFATC1—osteoporosis	2.15e-05	0.000319	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—KL—osteoporosis	2.14e-05	0.000317	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—DKK1—osteoporosis	2.13e-05	0.000316	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6R—osteoporosis	2.12e-05	0.000315	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PSMA5—osteoporosis	2.12e-05	0.000314	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—PSMA2—osteoporosis	2.12e-05	0.000314	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—WNT1—osteoporosis	2.09e-05	0.00031	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—POMC—osteoporosis	2.08e-05	0.000309	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—IDH2—osteoporosis	2.08e-05	0.000309	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—WNT1—osteoporosis	2.08e-05	0.000309	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP27A1—osteoporosis	2.08e-05	0.000308	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—WNT1—osteoporosis	2.07e-05	0.000308	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—IDH2—osteoporosis	2.06e-05	0.000306	CbGpPWpGaD
Paroxetine—TACR1—Signaling by GPCR—IL6—osteoporosis	2.06e-05	0.000306	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—WNT1—osteoporosis	2.05e-05	0.000305	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.04e-05	0.000302	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGA—osteoporosis	2.04e-05	0.000302	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.03e-05	0.000302	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6R—osteoporosis	2.03e-05	0.000302	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—P4HB—osteoporosis	2.03e-05	0.000301	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGA—osteoporosis	2.02e-05	0.0003	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ACP5—osteoporosis	2.02e-05	0.0003	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGA—osteoporosis	2.02e-05	0.000299	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—ADCY5—osteoporosis	2.01e-05	0.000298	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGA—osteoporosis	2e-05	0.000296	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—ADCY5—osteoporosis	1.99e-05	0.000296	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GAPDH—osteoporosis	1.99e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—ADCY5—osteoporosis	1.99e-05	0.000295	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—ADCY5—osteoporosis	1.97e-05	0.000292	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP27A1—osteoporosis	1.96e-05	0.00029	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP27A1—osteoporosis	1.94e-05	0.000288	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—RAP1A—osteoporosis	1.94e-05	0.000288	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ACP5—osteoporosis	1.9e-05	0.000282	CbGpPWpGaD
Paroxetine—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.9e-05	0.000282	CbGpPWpGaD
Paroxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.9e-05	0.000282	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—BMP2—osteoporosis	1.89e-05	0.000281	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PTHLH—osteoporosis	1.89e-05	0.000281	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ACP5—osteoporosis	1.89e-05	0.00028	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PTHLH—osteoporosis	1.88e-05	0.000279	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—BMP2—osteoporosis	1.88e-05	0.000279	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—TPI1—osteoporosis	1.88e-05	0.000279	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PTHLH—osteoporosis	1.88e-05	0.000278	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—BMP2—osteoporosis	1.88e-05	0.000278	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.86e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PTHLH—osteoporosis	1.86e-05	0.000276	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—BMP2—osteoporosis	1.86e-05	0.000276	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—FGB—osteoporosis	1.85e-05	0.000275	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ENO1—osteoporosis	1.85e-05	0.000275	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—FGB—osteoporosis	1.84e-05	0.000273	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—FGB—osteoporosis	1.84e-05	0.000272	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PSMA5—osteoporosis	1.82e-05	0.000271	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—PSMA2—osteoporosis	1.82e-05	0.000271	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—FGB—osteoporosis	1.82e-05	0.00027	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PSMA2—osteoporosis	1.79e-05	0.000265	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—PSMA5—osteoporosis	1.79e-05	0.000265	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PSMA2—osteoporosis	1.78e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—PSMA5—osteoporosis	1.78e-05	0.000264	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PSMA2—osteoporosis	1.77e-05	0.000263	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—PSMA5—osteoporosis	1.77e-05	0.000263	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—TPI1—osteoporosis	1.77e-05	0.000263	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—P4HB—osteoporosis	1.77e-05	0.000262	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PSMA2—osteoporosis	1.75e-05	0.00026	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—PSMA5—osteoporosis	1.75e-05	0.00026	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—TPI1—osteoporosis	1.75e-05	0.00026	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ADCY5—osteoporosis	1.75e-05	0.000259	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GAPDH—osteoporosis	1.73e-05	0.000257	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—CYP19A1—osteoporosis	1.72e-05	0.000255	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—SPP1—osteoporosis	1.69e-05	0.000251	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.69e-05	0.000251	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—RAP1A—osteoporosis	1.69e-05	0.00025	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ADCY5—osteoporosis	1.67e-05	0.000248	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—CALCA—osteoporosis	1.67e-05	0.000247	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—P4HB—osteoporosis	1.66e-05	0.000247	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—CALCA—osteoporosis	1.66e-05	0.000246	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—CALCA—osteoporosis	1.65e-05	0.000245	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—P4HB—osteoporosis	1.65e-05	0.000245	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—CALCA—osteoporosis	1.64e-05	0.000243	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GAPDH—osteoporosis	1.63e-05	0.000242	CbGpPWpGaD
Paroxetine—HTR2A—GPCR downstream signaling—POMC—osteoporosis	1.62e-05	0.000241	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GAPDH—osteoporosis	1.62e-05	0.00024	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—SPP1—osteoporosis	1.62e-05	0.00024	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—MYC—osteoporosis	1.62e-05	0.00024	CbGpPWpGaD
Paroxetine—CHRM1—GPCR downstream signaling—POMC—osteoporosis	1.62e-05	0.00024	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—TGFB1—osteoporosis	1.61e-05	0.00024	CbGpPWpGaD
Paroxetine—CHRM3—GPCR downstream signaling—POMC—osteoporosis	1.61e-05	0.000239	CbGpPWpGaD
Paroxetine—CHRM2—GPCR downstream signaling—POMC—osteoporosis	1.59e-05	0.000237	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—RAP1A—osteoporosis	1.59e-05	0.000236	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—RAP1A—osteoporosis	1.58e-05	0.000234	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ENO1—osteoporosis	1.57e-05	0.000232	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PSMA2—osteoporosis	1.54e-05	0.000229	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—PSMA5—osteoporosis	1.54e-05	0.000229	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IRS2—osteoporosis	1.53e-05	0.000227	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—KL—osteoporosis	1.51e-05	0.000224	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—KL—osteoporosis	1.5e-05	0.000223	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—KL—osteoporosis	1.5e-05	0.000223	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—LEP—osteoporosis	1.5e-05	0.000222	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—KL—osteoporosis	1.48e-05	0.00022	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—CYP19A1—osteoporosis	1.48e-05	0.000219	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—POMC—osteoporosis	1.48e-05	0.000219	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—POMC—osteoporosis	1.47e-05	0.000218	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IRS2—osteoporosis	1.46e-05	0.000217	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—POMC—osteoporosis	1.46e-05	0.000217	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—POMC—osteoporosis	1.45e-05	0.000215	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6R—osteoporosis	1.44e-05	0.000214	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—LEP—osteoporosis	1.43e-05	0.000213	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6R—osteoporosis	1.43e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—ESR1—osteoporosis	1.43e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6R—osteoporosis	1.43e-05	0.000212	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6R—osteoporosis	1.41e-05	0.00021	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—ADCY5—osteoporosis	1.4e-05	0.000208	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—GPX1—osteoporosis	1.4e-05	0.000208	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.38e-05	0.000204	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—ESR1—osteoporosis	1.37e-05	0.000203	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ENO1—osteoporosis	1.36e-05	0.000202	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PSMA2—osteoporosis	1.34e-05	0.0002	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—PSMA5—osteoporosis	1.34e-05	0.0002	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IRS1—osteoporosis	1.33e-05	0.000198	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—MTHFR—osteoporosis	1.29e-05	0.000192	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ENO1—osteoporosis	1.29e-05	0.000191	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—POMC—osteoporosis	1.29e-05	0.000191	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IRS1—osteoporosis	1.28e-05	0.00019	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ENO1—osteoporosis	1.27e-05	0.000189	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PSMA2—osteoporosis	1.27e-05	0.000188	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—PSMA5—osteoporosis	1.27e-05	0.000188	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PSMA5—osteoporosis	1.26e-05	0.000186	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—PSMA2—osteoporosis	1.26e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6R—osteoporosis	1.25e-05	0.000186	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—CYP19A1—osteoporosis	1.25e-05	0.000186	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IGF1—osteoporosis	1.24e-05	0.000183	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—POMC—osteoporosis	1.23e-05	0.000183	CbGpPWpGaD
Paroxetine—TACR1—Signaling Pathways—IL6—osteoporosis	1.22e-05	0.000181	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—ADCY5—osteoporosis	1.21e-05	0.000179	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—GPX1—osteoporosis	1.2e-05	0.000179	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6R—osteoporosis	1.2e-05	0.000178	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ADCY5—osteoporosis	1.18e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IGF1—osteoporosis	1.18e-05	0.000176	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ADCY5—osteoporosis	1.18e-05	0.000175	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ADCY5—osteoporosis	1.17e-05	0.000174	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ADCY5—osteoporosis	1.16e-05	0.000173	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—SPP1—osteoporosis	1.15e-05	0.00017	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—SPP1—osteoporosis	1.14e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—SPP1—osteoporosis	1.14e-05	0.000169	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—SPP1—osteoporosis	1.13e-05	0.000167	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—MTHFR—osteoporosis	1.11e-05	0.000165	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—CYP19A1—osteoporosis	1.09e-05	0.000162	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS2—osteoporosis	1.04e-05	0.000154	CbGpPWpGaD
Paroxetine—CHRM3—Metabolism—POMC—osteoporosis	1.03e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS2—osteoporosis	1.03e-05	0.000153	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—CYP19A1—osteoporosis	1.03e-05	0.000153	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS2—osteoporosis	1.03e-05	0.000153	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—ADCY5—osteoporosis	1.02e-05	0.000152	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—GPX1—osteoporosis	1.02e-05	0.000151	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—CYP19A1—osteoporosis	1.02e-05	0.000151	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS2—osteoporosis	1.02e-05	0.000151	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—LEP—osteoporosis	1.01e-05	0.000151	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—LEP—osteoporosis	1.01e-05	0.00015	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—LEP—osteoporosis	1.01e-05	0.000149	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—LEP—osteoporosis	9.96e-06	0.000148	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—ESR1—osteoporosis	9.68e-06	0.000144	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—ESR1—osteoporosis	9.63e-06	0.000143	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—ESR1—osteoporosis	9.6e-06	0.000142	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—ESR1—osteoporosis	9.51e-06	0.000141	CbGpPWpGaD
Paroxetine—CHRM4—Signaling by GPCR—IL6—osteoporosis	9.46e-06	0.00014	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—MTHFR—osteoporosis	9.41e-06	0.00014	CbGpPWpGaD
Paroxetine—CHRM5—Signaling by GPCR—IL6—osteoporosis	9.06e-06	0.000134	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IRS1—osteoporosis	9.05e-06	0.000134	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IRS1—osteoporosis	9e-06	0.000134	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IRS1—osteoporosis	8.97e-06	0.000133	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—ADCY5—osteoporosis	8.91e-06	0.000132	CbGpPWpGaD
Paroxetine—CYP2B6—Metabolism—POMC—osteoporosis	8.89e-06	0.000132	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IRS1—osteoporosis	8.89e-06	0.000132	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—GPX1—osteoporosis	8.88e-06	0.000132	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—POMC—osteoporosis	8.71e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—POMC—osteoporosis	8.67e-06	0.000129	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—POMC—osteoporosis	8.64e-06	0.000128	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—POMC—osteoporosis	8.56e-06	0.000127	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6R—osteoporosis	8.5e-06	0.000126	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6R—osteoporosis	8.46e-06	0.000125	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6R—osteoporosis	8.43e-06	0.000125	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—ADCY5—osteoporosis	8.4e-06	0.000125	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IGF1—osteoporosis	8.38e-06	0.000124	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—GPX1—osteoporosis	8.37e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6R—osteoporosis	8.35e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IGF1—osteoporosis	8.34e-06	0.000124	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—ADCY5—osteoporosis	8.33e-06	0.000124	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IGF1—osteoporosis	8.31e-06	0.000123	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—GPX1—osteoporosis	8.3e-06	0.000123	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IGF1—osteoporosis	8.23e-06	0.000122	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—MTHFR—osteoporosis	8.2e-06	0.000122	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—MTHFR—osteoporosis	7.73e-06	0.000115	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—MTHFR—osteoporosis	7.66e-06	0.000114	CbGpPWpGaD
Paroxetine—CYP2C8—Metabolism—POMC—osteoporosis	7.53e-06	0.000112	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—MYC—osteoporosis	7.43e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—TGFB1—osteoporosis	7.41e-06	0.00011	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—MYC—osteoporosis	7.12e-06	0.000106	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—TGFB1—osteoporosis	7.1e-06	0.000105	CbGpPWpGaD
Paroxetine—ABCB1—Metabolism—POMC—osteoporosis	6.56e-06	9.73e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling by GPCR—IL6—osteoporosis	6.41e-06	9.51e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling by GPCR—IL6—osteoporosis	6.38e-06	9.46e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling by GPCR—IL6—osteoporosis	6.36e-06	9.43e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling by GPCR—IL6—osteoporosis	6.29e-06	9.34e-05	CbGpPWpGaD
Paroxetine—CYP2D6—Metabolism—POMC—osteoporosis	6.18e-06	9.17e-05	CbGpPWpGaD
Paroxetine—CYP2C9—Metabolism—POMC—osteoporosis	6.12e-06	9.09e-05	CbGpPWpGaD
Paroxetine—CHRM4—Signaling Pathways—IL6—osteoporosis	5.59e-06	8.29e-05	CbGpPWpGaD
Paroxetine—CHRM5—Signaling Pathways—IL6—osteoporosis	5.35e-06	7.94e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—MYC—osteoporosis	5.04e-06	7.47e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—TGFB1—osteoporosis	5.03e-06	7.46e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—MYC—osteoporosis	5.01e-06	7.43e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—TGFB1—osteoporosis	5e-06	7.42e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—MYC—osteoporosis	4.99e-06	7.41e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—TGFB1—osteoporosis	4.98e-06	7.39e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—MYC—osteoporosis	4.95e-06	7.34e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—TGFB1—osteoporosis	4.93e-06	7.32e-05	CbGpPWpGaD
Paroxetine—HTR2A—Signaling Pathways—IL6—osteoporosis	3.79e-06	5.62e-05	CbGpPWpGaD
Paroxetine—CHRM1—Signaling Pathways—IL6—osteoporosis	3.77e-06	5.59e-05	CbGpPWpGaD
Paroxetine—CHRM3—Signaling Pathways—IL6—osteoporosis	3.75e-06	5.57e-05	CbGpPWpGaD
Paroxetine—CHRM2—Signaling Pathways—IL6—osteoporosis	3.72e-06	5.52e-05	CbGpPWpGaD
